MwanzoRARE • NASDAQ
add
Ultragenyx Pharmaceutical Inc
$ 43.16
Baada ya Saa za Kazi:(0.00%)0.00
$ 43.16
Imefungwa: 13 Jan, 16:34:45 GMT -5 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 42.07
Bei za siku
$ 40.50 - $ 43.23
Bei za mwaka
$ 37.02 - $ 60.37
Thamani ya kampuni katika soko
3.99B USD
Wastani wa hisa zilizouzwa
elfu 820.16
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 139.49M | 42.27% |
Matumizi ya uendeshaji wa biashara | 250.46M | 7.88% |
Mapato halisi | -133.52M | 16.37% |
Kiwango cha faida halisi | -95.71 | 41.22% |
Mapato kwa kila hisa | -1.40 | 37.22% |
EBITDA | -123.23M | 10.64% |
Asilimia ya kodi ya mapato | -0.23% | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 607.51M | 37.42% |
Jumla ya mali | 1.54B | 24.25% |
Jumla ya dhima | 1.18B | -1.81% |
Jumla ya hisa | 353.83M | — |
hisa zilizosalia | 92.28M | — |
Uwiano wa bei na thamani | 11.19 | — |
Faida inayotokana na mali | -20.90% | — |
Faida inayotokana mtaji | -25.14% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Sep 2024info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -133.52M | 16.37% |
Pesa kutokana na shughuli | -67.00M | 43.16% |
Pesa kutokana na uwekezaji | -275.50M | -528.50% |
Pesa kutokana na ufadhili | 11.17M | -55.72% |
Mabadiliko halisi ya pesa taslimu | -330.05M | -1,035.71% |
Mtiririko huru wa pesa | -23.26M | 65.84% |
Kuhusu
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.
Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami.
Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2010
Makao Makuu
Tovuti
Wafanyakazi
1,276
